Uncategorized
Novartis Buys Breast Cancer Drug for $2B to Keep Up With Myriad Rivals
Aside from the $2 billion upfront payment, Novartis is also putting up to $1 billion on the line in milestones for Synnovation Therapeutics’ pan-mutant-selective PI3Kα blocker.